MaxCyte, Inc. Notice of Results (5833K)

TIDMMXCT TIDMTTM

RNS Number : 5833K

MaxCyte, Inc.

02 September 2021

MaxCyte to Report Second Quarter 2021 Financial Results on September 13, 2021

GAITHERSBURG, MD, September 02, 2021 - MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for ex vivo cell engineering, today announced that it will release financial results for the second quarter of 2021 after the U.S. market close on Monday, September 13(th) , 2021. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.

Conference Call Details

Interested parties may access the live teleconference by dialing (844) 679-0933 for domestic callers or (918) 922-6914 for international callers, followed by Conference ID: 3199124. A live and archived webcast of the event will be available on the "Events" section of the MaxCyte website at https://investors.maxcyte.com/ .

About MaxCyte

MaxCyte is a leading provider of cell-engineering platform technologies to advance innovative cell-based research, development and potential commercialization of next-generation cell therapies. The Company's existing customer base ranges from large biopharmaceutical companies - including 20 of the top 25 pharmaceutical companies based on 2020 global revenue - to hundreds of biotechnology companies and academic translational centers. MaxCyte has granted 14 strategic platform licenses to commercial cell therapy developers that allow for more than 75 clinical programs. Founded in 1998, MaxCyte is headquartered in Gaithersburg, Maryland, US.

MaxCyte Contacts:

 
 
  MaxCyte Inc. 
  Doug Doerfler, Chief Executive Officer 
  Amanda Murphy, Chief Financial Officer         +1 301-944-1660 
Nominated Adviser and Joint Corporate Broker 
 Panmure Gordon 
 Emma Earl / Freddy Crossley 
 Corporate Broking 
 Rupert Dearden                                  +44 (0)20 7886 2500 
 
  Joint Corporate Broker 
  Numis Securities Limited 
  James Black / Duncan Monteith / Matthew 
  O'Dowd                                         +44 (0)20 7260 1000 
Joint Corporate Broker 
 Stifel Nicolaus Europe Limited 
 Healthcare Investment Banking 
 Nicholas Moore / Ben Maddison / Samira 
 Essebiyea 
 Corporate Broking 
 Nick Adams                                      +44 (0) 20 7710 7600 
UK IR Adviser 
 Consilium Strategic Communications              +44 (0)203 709 5700 
 Mary-Jane Elliott                               maxcyte@consilium-comms.com 
 Chris Welsh 
US IR Adviser 
 Gilmartin Group                                 +1 415-937-5400 
 David Deuchler, CFA                             ir@maxcyte.com 
US Media Relations 
 Jamie Lacey-Moreira                             +1 410 299-3310 
 PressComm PR, LLC                               jamielacey@presscommpr.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORLTMJTMTTMBJB

(END) Dow Jones Newswires

September 02, 2021 09:26 ET (13:26 GMT)

Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024